|
|
|
|
|
|
| Prolongation of corneal allograft survival by topical application of Everolimus in a rat model |
|
| 作者：Li XQ, B… 文章来源：Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, wuhan, China 点击数896 更新时间：2006/6/29 22:11:10 文章录入：xq.lee 责任编辑：毛进 |
|
|
|
| Background. Everolimus is a novel proliferation signal inhibitor with potent immunosuppressant effects that holds promise to prevent acute allograft rejection. Commonly, topical application of immune modulatory agents is preferred to its systemic use to reduce side effects of the drug.
Purpose. Here we evaluated the efficacy of topical administration of Everolimus on experimental corneal grafts.
Methods. A total of 16 female Lewis rats received 3.5 mm MHC I/II incompatible corneal grafts of DA donors. Recipients were randomly assigned to receive either, 0.05% Everolimus in a microemulsion formulation (1) or the drug vehicle (2) as control. All treatments were started at the day of surgery and applied five times daily for 35 days. Grafts were graded every day and a rejection score was generated based on cornea clarity and oedema.
Results. Local administration of Everolimus was effective in prolonging the mean survival time of corneal grafts (MST 21 +/- 7.4 days) as compared to vehicle control group (13.3+/- 1.7 days; p=0.013).
Conclusions. These data indicate that topically applied Everolimus significantly prolonged the corneal allograft survival in an experimental keratoplasty model.
(Supported in part by DFG Pl 150-14/2)
|
|
|
|
|
|
|
|
|
|
